.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the sign "BIOA," according to papers filed with the Securities and Substitution Percentage. The firm has not publicly discussed an assumed financial amount for the offering.The clinical-stage firm proclaims lead prospect azelaprag, an orally provided tiny molecule slated to get in stage 2 testing in combination along with semaglutide-- sold through Novo Nordisk under brand Wegovy for fat burning-- in the 1st one-half of following year. Semaglutide is actually additionally sold as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is designed to blend effectively with GLP-1 drugs, enhancing fat burning while protecting muscular tissue mass. The investigational drug was discovered to be well-tolerated among 265 individuals throughout eight period 1 tests, depending on to BioAge.Formerly, BioAge amassed the assistance of Lilly to operate a trial blending azelaprag with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and Zepbound for fat burning. The partners are currently performing a phase 2 test of azelaprag and also tirzepatide, along with topline outcomes assumed in the 3rd one-fourth of 2025.The biotech is also organizing an insulin sensitivity proof-of-concept test analyzing azelaprag as a monotherapy in the 1st half of following year to sustain possible evidence development. Furthermore, the company prepares to talk to the FDA for consent in the second half of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic conditions and also neuroinflammation.BioAge's expected relocate to everyone market complies with a small uptick in organized biotech IPOs from Bicara Therapies as well as Zenas Biopharma. Zooming out, the recent IPO yard is actually a "mixed image," along with top quality business still debuting on the general public markets, just in lowered numbers, depending on to PitchBook.